Boehringer Ingelheim

Boehringer Ingelheim ADA2026 BI
Biotech

ADA: Tolerability questions linger for Boehringer's obesity drug

A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Fraiser Kansteiner Jun 8, 2026 4:30am
Berlin Germany Brandenburg Gate
Favicon Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm
Three blocks displaying from left to right a person a handshake and another person

Boehringer makes €407M bet on Immunitas’ inflammatory asset

May 12, 2026 9:57am
obesity overweight weight loss weigh

Boehringer links dual agonist to 16.6% weight loss in phase 3

Apr 28, 2026 4:00am
red and yellow background with scissors

Click cuts staff after commercial deal restructuring

Apr 14, 2026 10:25am
Four white arrows pointing to computer trash can icon

Boehringer, Amgen scrap immunology assets, citing low potential

Apr 14, 2026 4:00am